Scarica l'app Stockscreener
99.98
1.06%
-1.07
Pre-mercato:
99.59
-0.39
-0.39%
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Forum
Previsione
Frazionamento azionario
Incyte Corp Borsa (INCY) Ultime notizie
NICE backs approval for Incyte’s Opzelura - The Pharma Letter
Incyte Earnings Underscore Shift From Jakafi Reliance To Broader Pipeline - Yahoo Finance
Does Incyte’s 2025 Beat And 2026 Guidance Shift The Bull Case For INCY? - Yahoo Finance
Incyte Corp (NASDAQ:INCY) Presents a Compelling Value Case with Strong Fundamentals - ChartMill
Incyte Stock Fell 7% Last Week. Here’s What the Rest of 2026 Could Look Like - TIKR.com
Incyte Corp. (INCY) Reports Q4 2025 Revenue Growth of 28% to $1.51B Driven by Jakafi and Opzelura Sales - Finviz
Aberdeen Group plc Grows Stock Position in Incyte Corporation $INCY - MarketBeat
Incyte Reports $5.14 Billion in 2025 Revenue, Issues 2026 Outlook - MyChesCo
Where is Incyte Corporation (INCY) Headed According to Analysts? - Finviz
Barclays Analyst Raises Price Target for Incyte (INCY) to $117 | - GuruFocus
Incyte (INCY) Expands Latin American Partnership with Knight The - GuruFocus
The Top 5 Analyst Questions From Incyte's Q4 Earnings Call - Finviz
Incyte to Present at Upcoming Investor Conferences - Business Wire
How Incyte (NASDAQ:INCY) Drives Long-Term Growth In Nasdaq Composite - Kalkine Media
The Top 5 Analyst Questions From Incyte’s Q4 Earnings Call - Yahoo Finance
Incyte’s Opzelura Opportunity Is Getting Bigger—How Much Upside Does Moderate AD Unlock Internationally? - Smartkarma
Do Wall Street analysts like Incyte Corporation stock? - MSN
INCY Q4 earnings miss estimates, revenues beat on higher product sales - MSN
Cookson Peirce & Co. Inc. Acquires Shares of 11,331 Incyte Corporation $INCY - MarketBeat
Incyte’s weak Opzelura 2026 revenue forecast heightens Jakafi patent concerns (Feb 10) By Reuters - Investing.com
Incyte's weak Opzelura 2026 revenue forecast heightens Jakafi patent concerns - Reuters
Is It Too Late To Consider Incyte (INCY) After Its 43% One Year Rally - Yahoo Finance
Incyte Corporation $INCY Shares Sold by Sound Shore Management Inc CT - MarketBeat
LSV Asset Management Buys 124,266 Shares of Incyte Corporation $INCY - MarketBeat
Illinois Municipal Retirement Fund Sells 15,073 Shares of Incyte Corporation $INCY - MarketBeat
Do Wall Street Analysts Like Incyte Corporation Stock? - Barchart.com
Do financial experts on Wall Street have a favorable opinion of Incyte Corporation shares? - Bitget
INCY: Stifel Raises Price Target to $120, Maintains Buy Rating | - GuruFocus
Incyte shifts course on downtown Wilmington project, sells Bracebridge buildings as state incentives face scrutiny - Delaware LIVE News
Incyte selling buildings and cutting back space at future downtown headquarters - Delaware Business Now
Incyte selling buildings and cut back space at future downtown headquarters - Delaware Business Now
Royal Bank Of Canada Cuts Incyte (NASDAQ:INCY) Price Target to $92.00 - MarketBeat
Incyte (INCY): RBC Capital Lowers Price Target to USD 92 | INCY Stock News - GuruFocus
Incyte (INCY) Analyst Ratings Update: Wells Fargo Lowers Price T - GuruFocus
Wells Fargo & Company Cuts Incyte (NASDAQ:INCY) Price Target to $101.00 - MarketBeat
INCY Q4 Deep Dive: Revenue Growth Outpaces Profit as Pipeline Advances, Margins Narrow - Finviz
Incyte Corporation (NASDAQ:INCY) Q4 2025 Earnings Call Transcript - Insider Monkey
INCY: HC Wainwright & Co. Reiterates Buy Rating, Maintains $135 Price Target | INCY Stock News - GuruFocus
Incyte Faces Growing Pains As It Looks To Build Post-Jakafi Foundation - Citeline News & Insights
Incyte Shares Surge on Strong Revenue Performance and Pipeline Progress - AD HOC NEWS
Incyte Faces Jakafi Patent Cliff; Focus on Opzelura and Advancing Pipeline to Offset Losses - Morningstar
Decoding Incyte Corp (INCY): A Strategic SWOT Insight - GuruFocus
Incyte: Fourth Quarter Earnings Overview - Bitget
Incyte (INCY) Shares Fall After Q4 Earnings Miss and Weak 2026 O - GuruFocus
Incyte Corporation Reports Strong 2025 Fiscal Results and Provides 2026 Guidance - AlphaStreet News
Incyte Corp. stock underperforms Tuesday when compared to competitors - MarketWatch
Incyte (INCY) Reports Strong Q4 and Annual Revenue Growth - GuruFocus
Incyte Q4 Earnings Call Highlights - Yahoo Finance
Incyte Corp (INCY) Q4 2025 Earnings Call Highlights: Strong Reve - GuruFocus
Incyte (INCY) Shares Fall After Q4 Earnings Miss and Weak 2026 Outlook - GuruFocus
Jefferies reiterates Buy rating on Incyte stock, maintains $120 price target - Investing.com Canada
Why Incyte (INCY) Stock Is Nosediving - Finviz
INCY Q4 Earnings Miss Estimates, Revenues Beat on Higher Product Sales - sharewise.com
Incyte (INCY) Releases Product Revenue and Expense Guidance for 2026 - GuruFocus
Incyte (NASDAQ:INCY) Shares Gap Down Following Weak Earnings - MarketBeat
Truist Securities reiterates Hold rating on Incyte stock, maintains $103 target - Investing.com
Incyte Q4 2025 slides: Revenue surges 28%, stock dips on EPS miss - Investing.com
Incyte (INCY) Q4 2025 Earnings Call Transcript - The Globe and Mail
Incyte (INCY) Faces Challenges with Opzelura as Jakafi Patent Expiry Looms - GuruFocus
Earnings call transcript: Incyte’s Q4 2025 revenue beats estimates, stock dips - Investing.com
Severe Asthma Market: High-Growth Opportunities for Investors to 2034 – DelveInsight | Sanofi, GlaxoSmithKline, EMS, Oneness Biotech, Incyte Corp, CSPC ZhongQi Pharma, AstraZeneca - Barchart.com
1.52%
1.68%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):